Comparative efficacy and safety of inhaled corticosteroids in asthma
- PMID: 10465863
Comparative efficacy and safety of inhaled corticosteroids in asthma
Abstract
Current guidelines emphasize the efficacy of inhaled corticosteroids for anti-inflammatory activity in asthma, and recommend higher doses and earlier initiation of therapy than previous guidelines. Concern over possible side effects with long term use has prompted an evaluation of the available literature to determine the optimal dose that may be administered without fear that significant side effects might occur (e.g., growth retardation in children, adrenal suppression, reduction in bone mineral density, cataract formation). Regular treatment with the following drugs in adults and children, respectively, is unlikely to result in any clinically significant effects on the above parameters: beclomethasone dipropionate less than 1500 micrograms and 400 micrograms, budesonide less than 1600 micrograms and 400 micrograms, flunisolide less than 2000 micrograms and 1000 micrograms, fluticasone propionate approximately 500 micrograms and 200 micrograms, and triamcinolone acetonide less than 1600 micrograms and 1200 micrograms. Systemic effects are influenced by potency and bioavailability. Inhaled corticosteroids owe their favourable safety profile to a high topical to systemic potency ratio compared with that of oral corticosteroids. In terms of relative topical potency, fluticasone propionate is more potent than budesonide, which is more potent than beclomethasone dipropionate, which is more potent than flunisolide and triamcinolone acetonide. The delivery device has an important influence on the amount of drug reaching the patient. A spacer device attached to a metered dose inhaler or a Turbuhaler reduces oropharyngeal deposition and increases lung deposition. As a result, a dosage reduction may be possible, and local side effects of dysphonia and oral candidiasis may be reduced. Patients requiring continued high doses by the inhaled route should be monitored for systemic effects and be considered for osteoporosis prevention therapy if appropriate.
Comment in
-
Recent drug-related adverse events with inhaled corticosteroids that should be considered in patients at risk.Can J Clin Pharmacol. 1999 Summer;6(2):84. Can J Clin Pharmacol. 1999. PMID: 10576961 No abstract available.
Similar articles
-
Aseptic femoral head necrosis in a patient receiving long term courses of inhaled and intranasal corticosteroids.Tuberk Toraks. 2007;55(2):182-5. Tuberk Toraks. 2007. PMID: 17602347
-
Controversies involving inhaled beta-agonists and inhaled corticosteroids in the treatment of asthma.Clin Chest Med. 1995 Dec;16(4):715-33. Clin Chest Med. 1995. PMID: 8565410 Review.
-
[Systemic side effects of long-term treatment with low dose inhaled corticosteroids in children with asthma].Zhonghua Jie He He Hu Xi Za Zhi. 2001 Dec;24(12):740-3. Zhonghua Jie He He Hu Xi Za Zhi. 2001. PMID: 11930704 Clinical Trial. Chinese.
-
Clinical pharmacology of corticosteroids in bronchial asthma.Pharmacol Ther. 1993;58(2):173-209. doi: 10.1016/0163-7258(93)90049-j. Pharmacol Ther. 1993. PMID: 8415878 Review.
-
[Effectiveness and safety of fluticasone propionate in therapy of children suffering from asthma. Part II. Safety aspects of therapy with fluticasone propionate in asthmatic children].Pol Merkur Lekarski. 2004;17 Suppl 2:11-8. Pol Merkur Lekarski. 2004. PMID: 15688664 Review. Polish.
Cited by
-
Molecular dissection of an inhibitor targeting the HIV integrase dependent preintegration complex nuclear import.Cell Microbiol. 2019 Jan;21(1):e12953. doi: 10.1111/cmi.12953. Epub 2018 Sep 27. Cell Microbiol. 2019. PMID: 30216959 Free PMC article.
-
Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects.Eur J Clin Pharmacol. 2005 May;61(3):203-8. doi: 10.1007/s00228-005-0910-0. Epub 2005 Apr 12. Eur J Clin Pharmacol. 2005. PMID: 15824911 Clinical Trial.
-
Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review.BMC Fam Pract. 2006 Jun 5;7:34. doi: 10.1186/1471-2296-7-34. BMC Fam Pract. 2006. PMID: 16753053 Free PMC article.
-
Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber Plus spacer for inhalation.Clin Pharmacokinet. 2006;45(7):729-36. doi: 10.2165/00003088-200645070-00007. Clin Pharmacokinet. 2006. PMID: 16802853 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials